Bull
$4.84
シナリオ価格
$1.000
+0.009 (+0.94%)終値時点
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Given the current price of $1.00 and the RSI of 20.266 indicating oversold conditions, GNTA may present a potential buying opportunity in the long term. However, the significant 1-year change of -71.65% raises concerns about the company's stability and market performance.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Sòphia HT Unveils ROMAN Robotic Arm for Nuclear Fusion Maintenance

Sòphia HT Reports Significant Growth in FY2025 Financials

Genenta Science Acquires Majority Stake in Sòphia High Tech

Genenta Acquires Sòphia High Tech to Advance Strategic Consolidation

Genenta Science Transforms to Saentra Forge, Focused on Strategic Industrial Consolidation
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States. It operates in the Healthcare sector.
Given the current price of $1.00 and the RSI of 20.266 indicating oversold conditions, GNTA may present a potential buying opportunity in the long term. However, the significant 1-year change of -71.65% raises concerns about the company's stability and market performance.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。